CAJ | 학술논문

目的：通过实验研究扶正抗癌方对H22荷瘤小鼠的抑瘤作用及其对IL‐12和Survivin表达的影响。方法：85只小鼠，随机抽取15只作为正常对照组（A ），将剩余70只小鼠共同造模：在右腋皮下种植相同量的H22瘤株悬液，将造膜成功的小鼠随机纳入60只，采用每只右腋皮下接肝癌细胞悬液0．2 m L再随机分成4组，于接种瘤细胞悬液24小时候开始给药。空白对照组（A）：用生理盐水0．2mL／只／d；荷瘤对照组（B）：用生理盐水0．2mL／只／d；连续给药14d ，替加氟组（C）：给予替加氟配置的液体灌胃0．2mL／只／d；扶正抗癌方组（D）：浓度为1．89g／mL的中药煎剂灌胃，0．2mL／20g ，1次／d ，连续共14d ；（扶正抗癌方组＋替加氟组）联合用药组（E）组：扶正抗癌方浓缩浓度为3．78g／mL ，0．1mL／20g ，1次／d ，替加氟浓缩浓度为30mg／mL的水溶液灌胃，0．1mL／20g ，1次／d ，联合灌胃。经口灌胃14d后，取瘤体称重，用免疫组化法检测各组IL‐12和Survivin的表达。结果：联合用药组及、扶正抗癌方组、替加氟组各治疗组瘤组织Survivin表达显著下降，与荷瘤对照组比较具有非常显著性差异（P＜0．01）；IL‐12检测结果示：联合用药组与扶正抗癌方组及替加氟组比较具有显著性差异（P＜0．05），扶正抗癌方组与替加氟组比较无显著性差异（P＞0．05）；结论：扶正抗癌方具有抑制肝癌侵袭转移的作用，联合西药治疗可减毒增效，提高免疫功能，改善生存质量；其机制与抗肿瘤下调抑制细胞凋亡的Survivin同时促进IL‐12的表达及抗肿瘤侵袭与转移有关。
목적：통과실험연구부정항암방대H22하류소서적억류작용급기대IL‐12화Survivin표체적영향。방법：85지소서，수궤추취15지작위정상대조조（A ），장잉여70지소서공동조모：재우액피하충식상동량적H22류주현액，장조막성공적소서수궤납입60지，채용매지우액피하접간암세포현액0．2 m L재수궤분성4조，우접충류세포현액24소시후개시급약。공백대조조（A）：용생리염수0．2mL／지／d；하류대조조（B）：용생리염수0．2mL／지／d；련속급약14d ，체가불조（C）：급여체가불배치적액체관위0．2mL／지／d；부정항암방조（D）：농도위1．89g／mL적중약전제관위，0．2mL／20g ，1차／d ，련속공14d ；（부정항암방조＋체가불조）연합용약조（E）조：부정항암방농축농도위3．78g／mL ，0．1mL／20g ，1차／d ，체가불농축농도위30mg／mL적수용액관위，0．1mL／20g ，1차／d ，연합관위。경구관위14d후，취류체칭중，용면역조화법검측각조IL‐12화Survivin적표체。결과：연합용약조급、부정항암방조、체가불조각치료조류조직Survivin표체현저하강，여하류대조조비교구유비상현저성차이（P＜0．01）；IL‐12검측결과시：연합용약조여부정항암방조급체가불조비교구유현저성차이（P＜0．05），부정항암방조여체가불조비교무현저성차이（P＞0．05）；결론：부정항암방구유억제간암침습전이적작용，연합서약치료가감독증효，제고면역공능，개선생존질량；기궤제여항종류하조억제세포조망적Survivin동시촉진IL‐12적표체급항종류침습여전이유관。
Objective:An experimental study fuzheng anti‐carcinoma prescription cancer H22 square inhibitory effect on tumor‐bearing mice and their IL‐12 and Survivin expression .Methods :85 mice were randomly selected 15 as the normal control group (A) ,the remaining 70 mice were common modeling :the same amount in the right axillary subcuta‐neous tumor strain H22 grown in suspension ,will make the film successful in mice included 60 randomized ,using each ac‐cess right axillary subcutaneous hepatoma cell suspension 0 .2mL then randomly divided into four groups ,the cell suspen‐sion was administered at the beginning of 24 childhood tumor inoculation .The control group (A):saline 0 .2mL /only /day ;tumor‐bearing control group (B):with saline 0 .2mL /only /day ;14 days continuous administration ,tegafur group (C):give liquid tegafur configuration gavage 0 .2mL /only /day ;fuzheng anti‐carcinoma prescription group (D):the concentration of 1 .89g /mL herbal decoction ,0 .2mL /20g ,1 times /day for a total of 14 days;(fuzheng anti‐carcino ma prescription group + tegafur group) combination group (E) group:righting cancer square concentrate concentration 3 .78g /mL ,0 .1mL /20g ,1 times /day ,tegafurconcentrate concentration aqueous solution of 30mg /mL of gavage ,0 . 1mL /20g ,1 times /day ,the United gavage .By oral gavage for 14 days ,take the tumor weighed ,The expression of IL‐12 and Survivin detected by immunohistochemistry .Results :The combined group and ,fuzheng anti‐carcinoma prescrip‐tion group ,tegafur group in each treatment group tumor Survivin expression was significantly decreased ,and the tumor‐bearing control group has a very significant difference (P <0 .01);IL‐12 test results show :combination therapy group and fuzheng anti‐carcinoma prescription group and tegafur party group has significant difference (P <0 .05) ,no signifi‐cant differences fuzheng anti‐carcinoma prescription group and tegafur group (P> 0 .05);Conclusion:Righting antican‐cer square inhibit invasion and metastasis of hepatocellular carcinoma ,combined western medicine can be attenuated effi‐ciency ,improve immune function ,improve quality of life;and the mechanism of anti‐tumor cell apoptosis inhibition re‐duced Survivin expression while promoting IL‐12 and anti‐tumor invasion and metastasis .